Management strategy for drug resistance of chronic hepatitis B with nucleoside (acid) analogues
-
-
[1] 中华医学会感染病分会, 中华医学会肝病学分会.第十四次全国病毒性肝炎及肝病学术会议论文汇编[C].2009:1-19. [2]李国钦, 张燕.耐药性伤寒杆菌的流行及治疗[J].中华传染病杂志, 1990, 8 (1) :33-36. [3]李国钦, 李智山.鼠伤寒杆菌感染的治疗分析[J].临床内科杂志, 1990, 7 (4) :20-21. [4]李国钦.耐碳青霉烯鲍曼不动杆菌研究进展[J].中国感染控制杂志, 2008, 7 (2) :140-143. [5]Wursthorn K, Lutgehetmann M, Dandri M, et al.Peginterferon Al-pha-2b Plus Adefovir Induce Strong cccDNA Decline and HBsAg Reduction in Patients With Chronic Hepatitis B[J].Hepatology, 2006, 4 (3) :675-684. [6]Laras A, Koskinas J, Dimou E, et al.intrahepatic Levels and Repli-cative Activity of Covalently Closed Circular Hepatitis B Virus DNA in Chronically Infected Patients[J].Hepatology, 2006, 4 (3) :694-702. [7]Yim HJ, Hussain M.Liu Y et al.Evolution of Multi-Drug Resist-ant Hepatitis B Virus During Sequential Therapy[J].Hepatology, 2006, 44 (3) :703-712. [8]Perrillo RP.Therapy of Hepatitis B-Viral Suppression or Eradica-tion-[J].Hepatology, 2006, 43 (suppl1) :S182-S191.
本文二维码
计量
- 文章访问数: 187
- HTML全文浏览量: 7
- PDF下载量: 134
- 被引次数: 0